File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses
  • Basic View
  • Metadata View
  • XML View
TitleAn M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses
 
AuthorsZhao, G1 2
Lin, Y2
Du, L3
Guan, J1
Sun, S1
Sui, H2
Kou, Z1
Chan, CC2
Guo, Y1
Jiang, S3
Zheng, BJ2
Zhou, Y1
 
Issue Date2010
 
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.virologyj.com/home/
 
CitationVirology Journal, 2010, v. 7 [How to Cite?]
DOI: http://dx.doi.org/10.1186/1743-422X-7-9
 
AbstractBackground. A growing concern has raised regarding the pandemic potential of the highly pathogenic avian influenza (HPAI) H5N1 viruses. Consequently, there is an urgent need to develop an effective and safe vaccine against the divergent H5N1 influenza viruses. In the present study, we designed a tetra-branched multiple antigenic peptide (MAP)-based vaccine, designated M2e-MAP, which contains the sequence overlapping the highly conserved extracellular domain of matrix protein 2 (M2e) of a HPAI H5N1 virus, and investigated its immune responses and cross-protection against different clades of H5N1 viruses. Results. Our results showed that M2e-MAP vaccine induced strong M2e-specific IgG antibody responses following 3-dose immunization of mice with M2e-MAP in the presence of Freunds' or aluminium (alum) adjuvant. M2e-MAP vaccination limited viral replication and attenuated histopathological damage in the challenged mouse lungs. The M2e-MAP-based vaccine protected immunized mice against both clade1: VN/1194 and clade2.3.4: SZ/406H H5N1 virus challenge, being able to counteract weight lost and elevate survival rate following lethal challenge of H5N1 viruses. Conclusions. These results suggest that M2e-MAP presenting M2e of H5N1 virus has a great potential to be developed into an effective subunit vaccine for the prevention of infection by a broad spectrum of HPAI H5N1 viruses. © 2010 Zhao et al; licensee BioMed Central Ltd.
 
ISSN1743-422X
2013 Impact Factor: 2.089
2013 SCImago Journal Rankings: 1.023
 
DOIhttp://dx.doi.org/10.1186/1743-422X-7-9
 
PubMed Central IDPMC2823673
 
ISI Accession Number IDWOS:000275091300001
Funding AgencyGrant Number
National High Technology R&D Program of China2006AA02Z406
National Basic Research Program of China2005CB523001
National Natural Science Foundation of China30901371
Mega-projects of Science Research2009ZX10004-4001
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by the National High Technology R&D Program of China (863 Program, No. 2006AA02Z406), National Basic Research Program of China (973 Program, No. 2005CB523001), National Natural Science Foundation of China (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-4001), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

 
ReferencesReferences in Scopus
 
GrantsCross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice
Control of Pandemic and Inter-pandemic Influenza
 
DC FieldValue
dc.contributor.authorZhao, G
 
dc.contributor.authorLin, Y
 
dc.contributor.authorDu, L
 
dc.contributor.authorGuan, J
 
dc.contributor.authorSun, S
 
dc.contributor.authorSui, H
 
dc.contributor.authorKou, Z
 
dc.contributor.authorChan, CC
 
dc.contributor.authorGuo, Y
 
dc.contributor.authorJiang, S
 
dc.contributor.authorZheng, BJ
 
dc.contributor.authorZhou, Y
 
dc.date.accessioned2010-10-31T11:13:09Z
 
dc.date.available2010-10-31T11:13:09Z
 
dc.date.issued2010
 
dc.description.abstractBackground. A growing concern has raised regarding the pandemic potential of the highly pathogenic avian influenza (HPAI) H5N1 viruses. Consequently, there is an urgent need to develop an effective and safe vaccine against the divergent H5N1 influenza viruses. In the present study, we designed a tetra-branched multiple antigenic peptide (MAP)-based vaccine, designated M2e-MAP, which contains the sequence overlapping the highly conserved extracellular domain of matrix protein 2 (M2e) of a HPAI H5N1 virus, and investigated its immune responses and cross-protection against different clades of H5N1 viruses. Results. Our results showed that M2e-MAP vaccine induced strong M2e-specific IgG antibody responses following 3-dose immunization of mice with M2e-MAP in the presence of Freunds' or aluminium (alum) adjuvant. M2e-MAP vaccination limited viral replication and attenuated histopathological damage in the challenged mouse lungs. The M2e-MAP-based vaccine protected immunized mice against both clade1: VN/1194 and clade2.3.4: SZ/406H H5N1 virus challenge, being able to counteract weight lost and elevate survival rate following lethal challenge of H5N1 viruses. Conclusions. These results suggest that M2e-MAP presenting M2e of H5N1 virus has a great potential to be developed into an effective subunit vaccine for the prevention of infection by a broad spectrum of HPAI H5N1 viruses. © 2010 Zhao et al; licensee BioMed Central Ltd.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationVirology Journal, 2010, v. 7 [How to Cite?]
DOI: http://dx.doi.org/10.1186/1743-422X-7-9
 
dc.identifier.citeulike6564277
 
dc.identifier.doihttp://dx.doi.org/10.1186/1743-422X-7-9
 
dc.identifier.eissn1743-422X
 
dc.identifier.hkuros175099
 
dc.identifier.isiWOS:000275091300001
Funding AgencyGrant Number
National High Technology R&D Program of China2006AA02Z406
National Basic Research Program of China2005CB523001
National Natural Science Foundation of China30901371
Mega-projects of Science Research2009ZX10004-4001
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by the National High Technology R&D Program of China (863 Program, No. 2006AA02Z406), National Basic Research Program of China (973 Program, No. 2005CB523001), National Natural Science Foundation of China (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-4001), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

 
dc.identifier.issn1743-422X
2013 Impact Factor: 2.089
2013 SCImago Journal Rankings: 1.023
 
dc.identifier.issuearticle no. 9
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC2823673
 
dc.identifier.pmid20082709
 
dc.identifier.scopuseid_2-s2.0-77249104563
 
dc.identifier.urihttp://hdl.handle.net/10722/125131
 
dc.identifier.volume7
 
dc.languageeng
 
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.virologyj.com/home/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofVirology Journal
 
dc.relation.projectCross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice
 
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza
 
dc.relation.referencesReferences in Scopus
 
dc.rightsVirology Journal. Copyright © BioMed Central Ltd.
 
dc.subject.meshAdjuvants, Immunologic - administration and dosage
 
dc.subject.meshAntigens, Viral - immunology
 
dc.subject.meshInfluenza A Virus, H5N1 Subtype - immunology
 
dc.subject.meshInfluenza Vaccines - immunology
 
dc.subject.meshViral Matrix Proteins - immunology
 
dc.titleAn M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Zhao, G</contributor.author>
<contributor.author>Lin, Y</contributor.author>
<contributor.author>Du, L</contributor.author>
<contributor.author>Guan, J</contributor.author>
<contributor.author>Sun, S</contributor.author>
<contributor.author>Sui, H</contributor.author>
<contributor.author>Kou, Z</contributor.author>
<contributor.author>Chan, CC</contributor.author>
<contributor.author>Guo, Y</contributor.author>
<contributor.author>Jiang, S</contributor.author>
<contributor.author>Zheng, BJ</contributor.author>
<contributor.author>Zhou, Y</contributor.author>
<date.accessioned>2010-10-31T11:13:09Z</date.accessioned>
<date.available>2010-10-31T11:13:09Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Virology Journal, 2010, v. 7</identifier.citation>
<identifier.issn>1743-422X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/125131</identifier.uri>
<description.abstract>Background. A growing concern has raised regarding the pandemic potential of the highly pathogenic avian influenza (HPAI) H5N1 viruses. Consequently, there is an urgent need to develop an effective and safe vaccine against the divergent H5N1 influenza viruses. In the present study, we designed a tetra-branched multiple antigenic peptide (MAP)-based vaccine, designated M2e-MAP, which contains the sequence overlapping the highly conserved extracellular domain of matrix protein 2 (M2e) of a HPAI H5N1 virus, and investigated its immune responses and cross-protection against different clades of H5N1 viruses. Results. Our results showed that M2e-MAP vaccine induced strong M2e-specific IgG antibody responses following 3-dose immunization of mice with M2e-MAP in the presence of Freunds&apos; or aluminium (alum) adjuvant. M2e-MAP vaccination limited viral replication and attenuated histopathological damage in the challenged mouse lungs. The M2e-MAP-based vaccine protected immunized mice against both clade1: VN/1194 and clade2.3.4: SZ/406H H5N1 virus challenge, being able to counteract weight lost and elevate survival rate following lethal challenge of H5N1 viruses. Conclusions. These results suggest that M2e-MAP presenting M2e of H5N1 virus has a great potential to be developed into an effective subunit vaccine for the prevention of infection by a broad spectrum of HPAI H5N1 viruses. &#169; 2010 Zhao et al; licensee BioMed Central Ltd.</description.abstract>
<language>eng</language>
<publisher>BioMed Central Ltd. The Journal&apos;s web site is located at http://www.virologyj.com/home/</publisher>
<relation.ispartof>Virology Journal</relation.ispartof>
<rights>Virology Journal. Copyright &#169; BioMed Central Ltd.</rights>
<subject.mesh>Adjuvants, Immunologic - administration and dosage</subject.mesh>
<subject.mesh>Antigens, Viral - immunology</subject.mesh>
<subject.mesh>Influenza A Virus, H5N1 Subtype - immunology</subject.mesh>
<subject.mesh>Influenza Vaccines - immunology</subject.mesh>
<subject.mesh>Viral Matrix Proteins - immunology</subject.mesh>
<title>An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1743-422X&amp;volume=7&amp;issue=article no. 9&amp;spage=&amp;epage=&amp;date=2010&amp;atitle=An+M2e-based+multiple+antigenic+peptide+vaccine+protects+mice+from+lethal+challenge+with+divergent+H5N1+influenza+viruses</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1186/1743-422X-7-9</identifier.doi>
<identifier.pmid>20082709</identifier.pmid>
<identifier.pmcid>PMC2823673</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-77249104563</identifier.scopus>
<identifier.hkuros>175099</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77249104563&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>7</identifier.volume>
<identifier.issue>article no. 9</identifier.issue>
<identifier.eissn>1743-422X</identifier.eissn>
<identifier.isi>WOS:000275091300001</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<relation.project>Cross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice</relation.project>
<relation.project>Control of Pandemic and Inter-pandemic Influenza</relation.project>
<identifier.citeulike>6564277</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/125131/1/1743-422X-7-9.pdf</bitstream.url>
</item>
Author Affiliations
  1. Institute of Microbiology Chinese Academy of Sciences
  2. The University of Hong Kong
  3. New York Blood Center